IUPAC: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine · MW 211.27 g/mol · C₁₃H₁₃N₃ · CAS 249296-44-4 (base) / 375815-87-5 (tartrate) · ChEMBL1076903
Varenicline (Chantix · Champix · Tyrvaya). Rationally engineered from the plant alkaloid cytisine (Pfizer, CP-526,555) · the reference α4β2 nicotinic acetylcholine receptor partial agonist for smoking cessation · one small rigid molecule that does two opposing jobs — supplies just enough dopamine to hold withdrawal down, and occupies the receptor so inhaled nicotine can no longer light it up.
Varenicline is a high-affinity partial agonist at the α4β2 nicotinic acetylcholine receptor, the same pentameric cation channel that nicotine drives (see Nicotine #013). Where nicotine is a full agonist — binding the α4(+)/β2(−) orthosteric interface and pushing dopamine output to the ceiling — varenicline binds the identical pocket with roughly 1000-fold higher affinity (Ki ~0.06–0.15 nM vs nicotine's ~1 nM) but opens the channel only partially. That single difference in intrinsic efficacy is the whole drug.
The cessation logic falls straight out of partial agonism. In a smoker who has quit, varenicline occupies α4β2 and produces a submaximal, floor-level dopamine signal — enough to blunt craving and withdrawal without reproducing the smoking "hit". If that person then smokes, varenicline is already sitting in the pocket at sub-nanomolar affinity, so inhaled nicotine cannot outcompete it — the reinforcing spike is capped. It sets both a floor under withdrawal and a ceiling over relapse reward from the one binding site.
Binds the ACh orthosteric site at the α4/β2 interface — the aromatic box (Trp, Tyr) cation-π clamps varenicline's protonated secondary amine while the pyrazine and pyridine-like nitrogens H-bond. Sub-nanomolar Ki means near-continuous occupancy at clinical plasma levels.
Once bound, it gates the channel to only ~13–45% of the maximal nicotine/ACh current (intrinsic efficacy <1). This "just enough" dopamine is the pharmacological substrate of withdrawal relief without a full reward pulse.
Because affinity is ~1000× nicotine's, a resumed cigarette can't displace it. Varenicline behaves as a functional antagonist against inhaled nicotine — the "smoking a cigarette on Chantix feels flat" effect that undercuts relapse.
At the homomeric α7 receptor (Ki ~125 nM) varenicline is a full agonist, not partial. α7 signalling is implicated in cognition and in cortical/hippocampal circuits — a plausible contributor to the drug's effects on mood, attention, and vivid dreaming.
Weak partial agonism at ganglionic/area-postrema α3β4 (Ki ~75–86 nM) is the mechanistic price of imperfect β2 selectivity: it drives the signature dose-limiting nausea. β2 selectivity is good but not absolute.
An azabicyclo[3.3.1] bridge fused to a quinoxaline — zero rotatable bonds (ChEMBL RTB = 0). The rigidity pre-organises the pharmacophore into the α4β2 pocket, which is a large part of how a 211 Da molecule reaches sub-nanomolar affinity.
Contrast with the other cessation agents this maps onto: nicotine replacement supplies full agonist without combustion; bupropion works indirectly (dopamine/noradrenaline reuptake inhibition plus weak non-competitive nAChR antagonism); cytisine — varenicline's natural template — is itself a lower-affinity α4β2 partial agonist. Varenicline is the highest-affinity, most selective of the partial-agonist class.
Varenicline is pharmacokinetically clean and boring, by design. It is almost completely absorbed orally, undergoes minimal hepatic metabolism, and roughly 92% is excreted unchanged in urine. There is no meaningful CYP involvement — so unlike nicotine (CYP2A6) or bupropion (CYP2B6), varenicline is essentially free of the CYP-based drug–drug interactions that dog most psychiatric co-prescribing. It does not induce or inhibit the CYP enzymes either.
Clearance route: the drug is filtered at the glomerulus and actively secreted by the renal organic cation transporter 2 (OCT2, SLC22A2). What little metabolism occurs yields inactive products — N-glucuronidation and an N-carbamoylglucuronide, plus trace oxidation. No metabolite carries the pharmacology.
Clinical consequences of renal clearance: dose reduction is required in severe renal impairment (CrCl <30 mL/min) and in dialysis, because exposure rises when tubular secretion falls. OCT2 is the same transporter that handles metformin and cimetidine — competition is possible but clinically minor. The long ~24 h half-life is what permits simple once-to-twice-daily dosing and a fixed one-week up-titration (0.5 mg daily → 0.5 mg BID → 1 mg BID) that blunts early nausea.
A pharmacology footnote that is not about the molecule: in 2021 Pfizer recalled Chantix batches over N-nitroso-varenicline nitrosamine impurities above the acceptable intake limit — a manufacturing/storage issue in the tablet, unrelated to varenicline's intrinsic pharmacology, later managed with an interim higher acceptable-intake limit while supply was restored.
Varenicline is, on the evidence, the most effective single pharmacotherapy for smoking cessation. Cochrane meta-analyses put continuous abstinence at roughly 2.2–2.9× placebo, superior to single-form nicotine replacement and to bupropion, and comparable to combination NRT. The subjective effect is modest by design — it is not euphoric; it works by quietly removing the reason to smoke.
In the pivotal Gonzales/Jorenby trials (2006) and in EAGLES (Anthenelli et al., 2016), varenicline beat both placebo and bupropion on continuous abstinence, and beat the nicotine patch. Combination NRT (patch + fast-acting) is roughly competitive; varenicline + NRT or varenicline + bupropion combinations show incremental gains in some trials. It is the default first-line agent in most guidelines for a motivated quitter without contraindication.
Post-marketing reports of depressed mood, agitation, and suicidal ideation led the FDA to add a boxed warning in 2009. The definitive test was EAGLES — a large (~8,000-patient) randomised trial enriched for psychiatric history, comparing varenicline, bupropion, patch, and placebo. It found no significant increase in serious neuropsychiatric adverse events for varenicline versus placebo, in either the psychiatric or non-psychiatric cohort. On that evidence the FDA removed the boxed warning in December 2016. Vigilance for mood change in vulnerable patients remains sensible, but the original alarm was not confirmed by the controlled data.
Nausea is the dominant adverse effect (~30%, mostly mild–moderate, often waning) — mechanistically the α3β4 / area-postrema price of imperfect β2 selectivity; taking doses with food and water and using the slow titration blunts it. Abnormal, vivid, sometimes lurid dreams and insomnia are the other signature complaints, plausibly tied to α4β2/α7 engagement of REM-associated cholinergic circuits. Headache, constipation, and dysgeusia round out the common list. These, not catastrophe, are why real patients stop.
The same central α4β2 mechanism has driven off-label and repurposed interest: modest signals in alcohol use disorder (reduced heavy drinking in some trials), emerging use to help people quit e-cigarettes/vaping, and — as the separate product Tyrvaya — a low-dose nasal spray for dry-eye disease, exploiting nAChRs on the trigeminal parasympathetic pathway to drive basal tear production. Same molecule, three problems, one receptor family.
The design lesson is clean: take a plant partial agonist (cytisine), rigidify and tune the scaffold for α4β2 affinity and β2 selectivity, and you convert a folk anti-smoking remedy into a first-line, guideline-grade cessation drug whose entire therapeutic action is the gap between binding (sub-nanomolar) and gating (partial).
Clinical and non-moralising. Varenicline is a prescription cessation aid, not a recreational drug — the harm-reduction frame here is tolerability management and honest risk communication, so people can stay on an effective quit aid instead of abandoning it over manageable side effects. The health arithmetic is stark: continued smoking is far more dangerous than any documented varenicline risk.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
α4β2
Neuronal nAChR α4/β2 (CHRNA4/CHRNB2)
|
Ki ≈ 0.06–0.15 nM
EC₅₀ ~2.3 µM · partial
|
Partial agonist | |
|
α3β2 / α2β2
Other β2* neuronal nAChR subtypes
|
Ki ≈ 0.2–2.5 nM
|
Partial agonist | |
|
α7
Homomeric nAChR α7 (CHRNA7)
|
Ki ≈ 125 nM
full agonist (functional)
|
Full agonist | |
|
α3β4
Ganglionic nAChR α3/β4
|
Ki ≈ 75–86 nM
nausea liability
|
Weak partial agonist | |
|
α4β4
Neuronal nAChR α4/β4
|
Ki ≈ 15–110 nM
|
Partial agonist | |
|
Muscle
Muscle-type nAChR α1β1δγ
|
Ki ≈ 8,200 nM (weak)
|
Negligible |
Varenicline is an almost pathologically rigid ligand — a fused azabicyclo[3.3.1]/quinoxaline cage with zero rotatable bonds (ChEMBL RTB = 0). On binding it pays essentially no conformational-entropy penalty: there are no torsions to freeze out. The pharmacophore is pre-paid into the α4β2 pocket, so nearly all of the free energy of binding is enthalpic (cation-π on the protonated amine, H-bonds from the ring nitrogens). That is the structural reason a 211 Da molecule reaches a sub-nanomolar Ki — a ligand-side Shannon-entropy cost near zero.
The interesting ΔS is again on the receptor side, and here partial agonism has a clean entropic reading. Full agonists (nicotine, ACh) drive loop-C to cap tightly and collapse the pentamer deep into the low-entropy open/desensitised well. Varenicline binds even tighter but stabilises an intermediate conformational ensemble — a shallower collapse of accessible microstates that gates the channel only partway. In FlexAID∆S terms, the ~10⁴× gap between binding Ki (~0.1 nM) and gating EC₅₀ (~2 µM) is exactly this decoupling: maximal affinity, sub-maximal receptor entropy-contraction. The therapeutic effect is that gap.